PDL1 Antibody [5H6]

Blue Ice

Predicted: 32 kDa
Observed: 45 kDa

PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC) (1). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC (2). PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells (3). This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts. PD-L1 also functions as an immune checkpoint protein, and multiple anti-PD-L1 antibodies are currently in phase II and III clinical trials, with one antibody already approved for the treatment of cancer (4).

Trial Size

7661534

PRS-1340-0.1mg

1 mg/mL

PD-L1 antibody can be used for detection of PD-L1 by Western blot at 0.5 - 1 μ g/mL. Antibody can also be used for immunohistochemistry starting at 2 - 5 μ g/mL. For immunofluorescence start at 5μ g/mL.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples; Immunocytochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.

Monoclonal

Homo sapiens

Optimal dilutions for each application to be determined by the researcher.